ClinicalTrials.gg
CompletedNCT02693210Updated Nov 1, 2016

A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis

A Phase 2 interventional study of Cyclophosphamide and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 33 sites in 11 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2016-11-01.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
50th of 113
161 · median 130
Started
2001
with 1 other
Phase 2
10 of 113
2 open now
Registered
88th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 50th largest by enrollment, is one of 2 that started in 2001, is one of 10 in phase 2, and was the 88th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

WA16291 is a Phase IIa "proof-of-concept" study. The primary objective of this study is to determine the safety and efficacy of rituximab (a B cell depleting chimeric monoclonal antibody) used either as monotherapy or in combination with methotrexate or cyclophosphamide in participants with rheumatoid arthritis who have failed prior Disease Modifying Anti-Rheumatic Drug (DMARD) therapy and currently have an inadequate clinical response to methotrexate.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with moderate to severe rheumatoid arthritis (RA) who have previously failed 1-5 DMARDS who currently have partial clinical response to treatment with methotrexate
  • Using methotrexate as a single DMARD for at least 16 weeks, of which the last 4 weeks prior to baseline on a stable oral dose greater than or equal to (>=) 10 milligrams per week (mg/week)
  • >=21 years of age
  • Swollen Joint Count (SJC) and Tender Joint Count (TJC) >= 8 (out of 66 and 68 joints respectively)
  • At least 2 of the following parameters at Baseline: C- Reactive Protein >= 15 mg/dL; Erythrocyte Sedimentation Rate >= 30 millimeters per hour (mm/hr); Morning stiffness >45 minutes
  • Rheumatoid factor titer >=20 International units per milliliter (IU/mL)
  • (less than or equal to [=\<] 12.5 milligrams per deciliter [mg/d] prednisone or equivalent) or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are permitted if stable for at least 4 weeks prior to baseline

Exclusion criteria

Exclusion Criteria:

  • American Rheumatism Association (ARA) Class IV RA disease
  • Concurrent treatment with any DMARD (apart from randomized treatment) or anti-TNF-alpha therapy
  • Active infection or history of recurrent significant infection
  • Prior history of cancer including solid tumors and hematologic (except basal carcinoma of the skin that have been excised and cured)
  • Evidence of serious uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders
  • Bone/joint surgery within 6 weeks prior to screening
  • Rheumatic disease other than RA
  • Active rheumatoid vasculitis
  • Prior history of gout
  • Chronic fatigue syndrome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Active comparator
    Group A: Methotrexate

    Participants will receive methotrexate at dosage \>=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.

    Drug: Methotrexate · Other: Placebo Cyclophosphamide · Other: Placebo Rituximab

  • Experimental
    Group B: Rituximab Monotherapy

    Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.

    Other: Placebo Cyclophosphamide · Other: Placebo Methotrexate · Drug: Rituximab

  • Experimental
    Group C: Rituximab and Cyclophosphamide

    Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.

    Drug: Cyclophosphamide · Other: Placebo Methotrexate · Drug: Rituximab

  • Experimental
    Group D: Methotrexate and Rituximab

    Participants will receive \>=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.

    Drug: Methotrexate · Other: Placebo Cyclophosphamide · Drug: Rituximab

Interventions

  • Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17

  • Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks

  • OtherPlacebo Cyclophosphamide

    Participants will receive placebo in place of cyclophosphamide on Days 3 and 17

  • OtherPlacebo Methotrexate

    Participants will receive weekly oral placebo in place of Methotrexate

  • OtherPlacebo Rituximab

    Participants will receive placebo in place of rituximab on days 1 and 15

  • Participants will receive 1g infusions of rituximab on Days 1 and 15

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving American College of Rheumatology (ACR) 50 response at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Percentage of participants achieving ACR 20 and ACR 70 responses at Week 24

    Time frame: Week 24

  2. Area Under the Curve (AUC) of American College of Rheumatology Response (ACRn)

    Time frame: Baseline up to Week 24

  3. AUC of the mean Disease Activity Scores (DAS)

    Time frame: Baseline up to Week 24

  4. Change from Baseline in the Swollen Joint Count

    Time frame: Baseline, Weeks 12, 16, 20 and 24

  5. Change from Baseline in the Tender Joint Count

    Time frame: Baseline, Weeks 12, 16, 20 and 24

  6. Change from Baseline in participant's global assessment of disease activity using a Visual Analog Scale (VAS)

    Time frame: Baseline, Weeks 8, 12, 16, 20 and 24

  7. Change from Baseline in physician's global assessment of disease activity using VAS

    Time frame: Baseline, Weeks 8, 12, 16, 20 and 24

  8. Change from Baseline in the Health Assessment Questionnaire - Disease Index (HAQ-DI) scores

    Time frame: Baseline, Weeks 12, 16, 20 and 24

  9. Change from Baseline in participant's pain measured by VAS

    Time frame: Baseline, Weeks 12, 16, 20 and 24

  10. Change from Baseline in C-Reactive Protein (CRP) Levels

    Time frame: Baseline, Weeks 12, 16, 20 and 24

  11. Change from Baseline in Erythrocyte Sedimentation Rate (ESR)

    Time frame: Baseline, Weeks 12, 16, 20 and 24

  12. Mean change in Rheumatoid factor levels at 24 weeks

    Time frame: Baseline and Week 24

  13. Percentage of participants who withdrew due to insufficient therapeutic response

    Time frame: Up to 24 Weeks

07

Study locations

33 sites
  • Darlinghurst, 2010, Australia
  • Kogarah, 2217, Australia
  • Woodville, 5011, Australia
  • Diepenbeek, 3590, Belgium
  • Gent, 9000, Belgium
  • Liege, 4000, Belgium
  • Winnipeg, Manitoba R3A 1M4, Canada
  • Toronto, Ontario M5G 1X5, Canada
  • Montreal, Quebec H2L 1S6, Canada
  • Praha, 128 50, Czech Republic
  • Leipzig, 04107, Germany
  • Ratingen, 40882, Germany
  • Wiesbaden, 65191, Germany
  • Haifa, 31048, Israel
  • Haifa, 34354, Israel
  • Brescia, 25123, Italy
  • Genova, 16132, Italy
  • Modena, 41100, Italy
  • Siena, 53100, Italy
  • Leiden, 2333 ZA, Netherlands
  • Lublin, 20-022, Poland
  • Poznan, 61-545, Poland
  • Warszawa, 02-637, Poland
  • Wroclaw, 50-556, Poland
  • Guadalajara, 19002, Spain
  • La Laguna, 38320, Spain
  • Madrid, 28007, Spain
  • Madrid, 28046, Spain
  • Sevilla, 41014, Spain
  • Cannock, WS11 5XY, United Kingdom
  • Leeds, LS1 3EX, United Kingdom
  • London, W1P 9PG, United Kingdom
  • Stoke-on-trent, ST6 7AG, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001, a primary completion of Aug 2002 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2016
First posted
Feb 26, 2016
Start
Feb 2001
Primary completionActual
Aug 2002
CompletionActual
Aug 2004
Last update
Nov 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02693210
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 26, 2016
Start date
Feb 2001
Primary completion
Aug 2002
Completion
Aug 2004
Last update
Nov 1, 2016

Study contacts

Clinical Trials
study director · Hofffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Methotrexate · Rituximab

Start the discussion